Abbvie Header week 48

Abbvie Header week 48

X

Company profile for Altamira Therapeutics

Altamira Therapeutics

ALTAMIRA THERAPEUTICS

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

49 News

49 News

DEVELOPMENTS

19 Drug(s) in Development

19 Drug(s) in Development

Contact Supplier

Contact Supplier

Related Companies

Related Companies

We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders and central nervous system disorders. We are focusing on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These programs have gone through two Phase 1 trials and will move into proof-of-concept s...

We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders and central nervous system disorders. We are focusing on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These programs have gone through two Phase 1 trials and will move into proof-of-concept studies in 2019. In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus.

Sponsored Ad

pfizer-centreone-m-2022-12-05

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

pfizer-centreone-m-2022-12-05

Access Virtual Booth

Contact Supplier

Send me more info on How To Grow My Business Digitally?

Market Place

Home

Menu

Post Enquiry

Market Place

Search